Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research [PDF]
Frontiers in Cardiovascular Medicine, 2023 Pulmonary hypertension (PH) is characterized by pulmonary vascular remodeling and associated with adverse outcomes. In patients with PH, plasma aldosterone levels are elevated, suggesting that aldosterone and its receptor, the mineralocorticoid receptor (
Argen Mamazhakypov +2 more
doaj +2 more sources
Cardiac response to chronic restraint stress involves mineralocorticoid receptors in male Sprague–Dawley rats [PDF]
Physiological ReportsIn the present study, we aimed at elucidating whether exposure to chronic stress affects the expression of cardiac mineralocorticoid receptors (MRs), whether it influences cardiac structure and function, and whether MRs blockade attenuates the stress ...
D. Sztechman +4 more
doaj +2 more sources
Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension [PDF]
Pulmonary Circulation, 2021 Abnormalities that characterize pulmonary arterial hypertension include impairment in the structure and function of pulmonary vascular endothelial and smooth muscle cells.
Divya P. Menon +10 more
doaj +2 more sources
Influence of allelic variations in relation to norepinephrine and mineralocorticoid receptors on psychopathic traits: a pilot study [PDF]
PeerJ, 2018 Background Past findings support a relationship between abnormalities in the amygdala and the presence of psychopathic traits. Among other genes and biomarkers relevant to the amygdala, norepinephrine and mineralocorticoid receptors might both play a ...
Guillaume Durand
doaj +3 more sources
Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis. [PDF]
Frontiers in Endocrinology, 2015 Atherosclerosis is a chronic inflammatory disease of the vasculature that causes significant morbidity and mortality from myocardial infarction, stroke, peripheral vascular disease, and heart failure.
Mary Elizabeth Moss +3 more
doaj +2 more sources
Mineralocorticoid Receptor Antagonists [PDF]
International Cardiovascular Forum Journal, 2019 Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
+5 more sources
Pharmaceutics, 2023 Tacrolimus (Tac) is a calcineurin inhibitor commonly used as an immunosuppressor after solid organ transplantation. However, Tac may induce hypertension, nephrotoxicity, and an increase in aldosterone levels.
Stefanny M. Figueroa +5 more
doaj +1 more source
Localization of mineralocorticoid receptors at mammalian synapses. [PDF]
PLoS ONE, 2010 In the brain, membrane associated nongenomic steroid receptors can induce fast-acting responses to ion conductance and second messenger systems of neurons.
Eric M Prager +4 more
doaj +1 more source
Cell-specific mineralocorticoid receptors: future therapeutic targets for stroke?
Neural Regeneration Research, 2016 Quynh N Dinh +3 more
doaj +2 more sources
Cardiorenal benefits of finerenone: protecting kidney and heart
Annals of Medicine, 2023 Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors.
José R. González-Juanatey +5 more
doaj +1 more source